Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. LLY on Tuesday. Camurus granted Eli Lilly exclusive, worldwide rights to research ...

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal ® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology ...

Camurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops ...

If Eli Lilly can incorporate Camurus' FluidCrystal technology, its GLP-1 medicines might no longer need once-weekly dosing. That should make them more attractive and boost their already impressive ...

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compoundsCamurus eligible to receive up to $870 million in ...

Camurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops ...